Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment
Tango Therapeutics and Erasca have begun enrolment for a Phase I/II trial assessing the combination of oral therapies ERAS-0015 and vopimetostat in patients with lung and pancreatic cancers.
The post Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment appeared first on Clinical Trials Arena .